Trial Profile

Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC [non-small cell lung cancer] for Patients at Risk of Bleeding From VEGF Directed Therapies.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

30 Sep 2013 Planned end date changed from 1 Jul 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
30 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
02 Jul 2010 Enrolment in the first stage of the trial has been completed according to information presented at the 46th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com